Zacks Small Cap Comments on Lantern Pharma FY2024 Earnings

Lantern Pharma Inc. (NASDAQ:LTRN) – Equities research analysts at Zacks Small Cap lifted their FY2024 earnings per share (EPS) estimates for shares of Lantern Pharma in a report issued on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($1.90) for the year, up from their prior forecast of ($2.12). The consensus estimate for Lantern Pharma’s current full-year earnings is ($1.90) per share. Zacks Small Cap also issued estimates for Lantern Pharma’s Q4 2024 earnings at ($0.51) EPS and FY2025 earnings at ($1.86) EPS.

Lantern Pharma Stock Up 1.4 %

Shares of LTRN stock opened at $3.54 on Thursday. The business’s fifty day moving average is $3.59 and its 200 day moving average is $4.44. The stock has a market cap of $38.18 million, a price-to-earnings ratio of -1.99 and a beta of 1.58. Lantern Pharma has a twelve month low of $3.04 and a twelve month high of $11.99.

Institutional Trading of Lantern Pharma

A number of hedge funds and other institutional investors have recently modified their holdings of LTRN. Tocqueville Asset Management L.P. purchased a new position in Lantern Pharma during the 1st quarter valued at about $167,000. Renaissance Technologies LLC lifted its holdings in shares of Lantern Pharma by 24.5% during the second quarter. Renaissance Technologies LLC now owns 81,800 shares of the company’s stock valued at $382,000 after purchasing an additional 16,100 shares during the last quarter. CM Management LLC boosted its position in shares of Lantern Pharma by 23.1% in the 2nd quarter. CM Management LLC now owns 80,000 shares of the company’s stock worth $374,000 after purchasing an additional 15,000 shares in the last quarter. Westside Investment Management Inc. purchased a new stake in shares of Lantern Pharma in the 2nd quarter worth approximately $54,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Lantern Pharma by 55.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock worth $86,000 after buying an additional 6,585 shares during the last quarter. 28.62% of the stock is owned by hedge funds and other institutional investors.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.